DelveInsight’s Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Metastatic Colorectal Cancer Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Metastatic Colorectal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
Metastatic Colorectal Cancer: Overview
Colorectal cancer (CRC) is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. It is the third leading cause of death from cancer in the United States. According to the American Cancer Society, colorectal cancer is cancer that starts in the colon or the rectum; these cancers can also be named colon cancer or rectal cancer, depending on where they start. Also, most colorectal cancers (CRCs) start as a growth on the inner lining of the colon or rectum; these growths are called polyps.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market
Some of the key facts of the Metastatic Colorectal Cancer Market Report
- Globally, CRC is the third most commonly diagnosed cancer in males and the second in females, with 1.8 million new cases and almost 861,000 deaths in 2018, according to the World Health Organization GLOBOCAN database.
- According to the GLOBOCAN 2018 data, cancer of the colon has the fourth-highest incidence in the world, while cancer of the rectum is the eighth position. Together, CRCs are the third most commonly diagnosed form of cancer globally, comprising 11% of all cancer diagnoses.
- Through secondary research, it can be concluded that mCRC is more common in men as compared to women.
Metastatic Colorectal Cancer Market
The Metastatic Colorectal Cancer market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Metastatic Colorectal Cancer in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Metastatic Colorectal Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Metastatic Colorectal Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Metastatic Colorectal Cancer Treatment Market
The decision to opt for a treatment option for mCRC depends on several factors, including the extent of cancer and its reach to any other organs. While, usually, colon cancer spreads to the liver, It can also spread to the lungs, the lining of the abdomen (peritoneum), the ovaries, the brain, or other organs. Most often, a combination of the therapies are opted for better results. Currently, the most potential treatment options being used for mCRC are Surgery, Radiotherapy, Systemic Therapy, Targeted Therapy, Immunotherapy and Supportive care.
Metastatic Colorectal Cancer Market Insights
Currently, the treatment options and recommendations of CRC depend on several factors, including the type and stage of cancer, possible side effects, and the patient’s preferences, and overall health. The treatment options majorly include surgical resection in the early stages of cancer development followed by effective therapies which include radiation therapy, targeted therapy, immunotherapy and chemotherapy.
Metastatic Colorectal Cancer Epidemiology
The epidemiology section covers insights about the historical and current Metastatic Colorectal Cancer patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Metastatic Colorectal Cancer Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Colorectal Cancer market or expected to get launched in the market during the study period. The analysis covers Metastatic Colorectal Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Metastatic Colorectal Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Metastatic Colorectal Cancer Emerging Therapies
Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Pierre Fabre, along with others, there are several emerging key players, which are expected to change the dynamics of the Metastatic Colorectal Cancer (mCRC) market in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage, which includes AB Science (Masitinib), Merck Sharp and Dohme (Vicriviroc), Merck KGaA (Avelumab), Puma Biotechnology (Neratinib), Daiichi Sankyo (U3-1402), G1 therapeutics (Trilaciclib) along with several others that are under clinical development. The launch of these emerging therapies is expected during the forecast period of 2020–2030.
Metastatic Colorectal Cancer Companies
- Pfizer/Pierre Fabre
- Roche
- Taiho Oncology
- Eli Lilly
- Merck Sharp & Dohme
- AB Science
- Puma Biotechnology
- G1 Therapeutics, and Others
Metastatic Colorectal Cancer Drugs
- Trilaciclib
- Neratinib
- Avelumab
- Masitinib
- Keytruda
- Cyramza (Ramucirumab), and Others
Read Full Research Report @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Metastatic Colorectal Cancer Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/